INBX
Inhibrx Biosciences, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Inhibrx Biosciences, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
No other changes.
No other changes.
No thesis.
Annual filing, covered
10-K parsed · Mar 19 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 19 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
−8.91%
vs ±11.9% implied · ×0.75
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
shaded = implied · ▲▼ = realized
Inhibrx Biosciences, Inc.
76.72
+4.56 · +6.32%
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Inhibrx Biosciences, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Inhibrx Biosciences, Inc.'s 6 closest co-movers, none share that code.
Tall tick = annual report · Source: EDGAR
Linked news
| Manager | Value | % base | |
|---|---|---|---|
| Morgan Stanley | $123.9M | 9.45% | +3.56% |
| Perceptive | $123.0M | 9.38% | −10.05% |
| Sanofi | $109.7M | 8.37% | 0.00% |
| Viking Global Investors | $106.5M | 8.12% | −21.82% |
| Bank of America | $79.7M | 6.08% | +2473.63% |
| Manager | Value | % base | |
|---|---|---|---|
| Morgan Stanley | $123.9M | 9.45% | +3.56% |
| Perceptive | $123.0M | 9.38% | −10.05% |
| Sanofi | $109.7M | 8.37% | 0.00% |
| Viking Global Investors | $106.5M | 8.12% | −21.82% |
| Bank of America | $79.7M | 6.08% | +2473.63% |
—
Bull2
Bear1
Expected move
Inputs8Q avg ±5.5%·×2.05·rich
straddle ±15.7%
spot 72.16exp Nov 20ATM strike 70ATM straddle 13.30IV 105%